摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine

中文名称
——
中文别名
——
英文名称
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine
英文别名
5-(Aminomethyl)-6-(2,4-dichlorophenyl)-2-methylpyrimidin-4-amine
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine化学式
CAS
——
化学式
C12H12Cl2N4
mdl
——
分子量
283.16
InChiKey
SGJHOQOKDASCIO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    77.8
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    2-[(2,4-二氯苯基)亚甲基]丙二腈 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 9.0h, 生成 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine
    参考文献:
    名称:
    An aminomethylpyrimidine DPP-IV inhibitor with improved properties
    摘要:
    A recently identified DPP-IV inhibitor (1) was found to induce phospholipidosis and to inhibit CYP3A4. A small series of less lipophilic and less amphiphilic analogues was synthesized in an effort to overcome these issues. One compound from this series was equipotent to 1, did not induce phospholipidosis and showed a reduced CYP3A4 inhibition. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.04.048
点击查看最新优质反应信息

文献信息

  • Pyridine and pyrimidine derivatives
    申请人:——
    公开号:US20030216382A1
    公开(公告)日:2003-11-20
    The present invention provides compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 and X are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    本发明提供了化合物的公式(I)1,其中R1、R2、R3、R4和X如规范中所定义,以及其药用盐。这些化合物可用于治疗和/或预防与DPP IV相关的疾病,如糖尿病,特别是非胰岛素依赖型糖尿病和糖耐量受损。
  • NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES
    申请人:F. Hoffmann-La Roche AG
    公开号:EP1476435A1
    公开(公告)日:2004-11-17
  • US6867205B2
    申请人:——
    公开号:US6867205B2
    公开(公告)日:2005-03-15
  • US7022718B2
    申请人:——
    公开号:US7022718B2
    公开(公告)日:2006-04-04
  • [EN] NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE PYRIDINE ET DE PYRIMIDINE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2003068757A1
    公开(公告)日:2003-08-21
    The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
查看更多